Apellis Pharmaceuticals
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.
Top Stages
1 past transactions
Potentia Pharmaceuticals
Acquisition in 2014
Potentia Pharmaceuticals is a biotechnology company, develops anti-inflammatory drugs/therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.